Flash Therapeutics is a gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform and bioproduction technologies. The Company is built around the Vectalys lentiviral platform, which includes its patented non-integrative LentiFlash® technology, and integrative lentiviral vectors. By providing efficient, transient and short-term RNA delivery technology, LentiFlash® is suitable for gene editing and other advanced therapeutic approaches. When stable DNA expression is needed (e.g. immunotherapy such as CAR T cells), integrative lentiviral vectors will be the delivery method of choice. Both technologies benefit from novel production and purification processes developed and continually optimized since 2005. Flash Therapeutics was established in 2018 through the merger of FlashCell, a privately held company developing LentiFlash®, based RNA therapeutics; and Vectalys, a leading privately held 13-year old lentiviral vector manufacturer.